You are viewing the site in preview mode

Skip to main content

Advertisement

Table 5 Summary of phase 3 trials of sofosbuvir and ledipasvir in hepatitis C virus genotype 1

From: Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies

Study Population Treatment/Duration SVR12 rates
ION-1 HCV GT1 treatment-naïve including 15.7% (136/865) with cirrhosis SOF/LDV, 12 weeks 97.7% (209/214)
   SOF/LDV + RBV, 12 weeks 97.2% (211/217)
   SOF/LDV, 24 weeks NA (n = 217)
   SOF/LDV + RBV, 24 weeks NA (n = 217)
ION-2 HCV GT 1 treatment-experienced including 20.0% (88/440) with cirrhosis SOF/LDV, 12 weeks 93.6% (102/109)
   SOF/LDV+RBV, 12 weeks 96.4% (107/111)
   SOF/LDV, 24 weeks 99.1% (108/109)
   SOF/LDV+RBV, 24 weeks 99.1% (110/111)
ION-3 HCV GT1 treatment-naïve SOF/LDV, 8 weeks 94.0% (202/215)
   SOF/LDV + RBV, 8 weeks 93.1% (201/216)
   SOF/LDV, 12 weeks 95.4% (206/216)
  1. SVR: Sustained virologic response. HCV: Hepatitis C virus. GT: Genotype. SOF: Sofosbuvir. LDV: ledipasvir. RBV: ribavirin. NA: not available.